AlphAIAlphAI — Financial news for AI agents
fool.comAUG 126 min read$LIVN

LivaNova (LIVN) Q2 2026 Earnings Call Transcript

LivaNova (LIVN) reported Q2 2026 revenue of $390.6 million, up 10.8% reported and 9.8% constant currency, and adjusted diluted EPS of $1.26. Adjusted gross margin rose to 71.0%. Full-year 2026 revenue guidance was raised to 8% to 9% constant-currency growth, and adjusted EPS to $4.30 to $4.40, while free cash flow guidance was lowered to $140 million to $160 million.

Original reporting
fool.com
Published Aug 12, 2026, 4:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 12, 2026, 5:01 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
LivaNova (LIVN) Q2 2026 Earnings Call Transcript — source image
Source · fool.com
Decision brief

The 30-second read

$LIVNNeutralMed
01

Why it matters

The most tradable elements are the simultaneous guidance raise (revenue and adjusted EPS) and guidance cut (adjusted free cash flow), tied to capex and strategic investments, plus specific demand and reimbursement drivers.

02

Market read

Traders can reprice near-term expectations using the explicit guidance updates and cash-flow/capex trade-off described by management.

03

What to watch

The OSA PMA supplement timing was pushed to 2H26 to 1H27, which could delay upside from that program even as other segments show momentum.

Relevance 8/10Novelty 8/10Timing: post-call, for positioning ahead of next-quarter estimates and investor follow-through

Background

This is a Q2 2026 earnings call transcript summary for LivaNova, covering segment performance, reimbursement updates, clinical algorithm results, and full-year guidance changes.

Company-level read

Ticker impact

$LIVNNeutralMedium confidence
Context

LivaNova raised 2026 constant-currency revenue growth guidance to 8% to 9% and EPS to $4.30 to $4.40, while lowering free cash flow guidance to $140M to $160M.

Expected impact

Likely two-sided reaction: upside bias on raised revenue/EPS, offset by FCF reduction and capex ramp.

Evidence & confidence

The article provides specific, time-bound forecast changes (revenue/EPS up, FCF down) plus drivers (manufacturing and IT investments, Medicare reimbursement, tariff refund), which are actionable for positioning into subsequent quarters.

Market effects

Sector

Signals continued demand and share gains in cardiopulmonary and epilepsy devices, with reimbursement and manufacturing capacity as key swing factors.

Regional

Highlights stronger Europe and Rest-of-World growth versus U.S. growth, which may influence regional demand expectations for medtech peers.

Global

Tariff refund and component supply agreements underscore supply-chain and policy sensitivity in medical device manufacturing.

Counterpoint

What could challenge this read

Raised EPS and revenue may be partially offset by execution risk from the manufacturing line and IT investments that also drove the free cash flow guidance reduction.

Key entities

  • company
    LivaNova PLC

    Reported Q2 2026 results and updated full-year 2026 guidance, including revenue/EPS increases and free cash flow reduction.

  • counterparty
    Thermo Fisher Scientific

    Entered a long-term oxygenator component agreement with LivaNova to secure supply and reduce manufacturing bottlenecks.

  • regulator
    CMS

    Asked about RECOVER 36-month depression data, with formal consideration deferred until publication.

Read at source← All news

Related articles

OCT 23
$LIVNMed

LivaNova PLC: Neuromodulation Publishes Full 36-Month CORE-VNS Results Demonstrating Sustained and Increasing Benefits of LivaNova's VNS Therapy for Drug-Resistant Epilepsy

LivaNova PLC (LIVN) reported 36-month results from the CORE-VNS study, showing a 76% median reduction in seizure frequency for drug-resistant epilepsy patients using its VNS Therapy. The study also found improvements in quality of life, healthcare resource utilization, and seizure severity. The data was published in the journal Neuromodulation.

finanznachrichten.de3 min
OCT 23
$LIVNMedAI 8/10

A nerve-stimulation study found the share reporting seizure-related hospital stays fell 73% over three years.

LivaNova PLC (LIVN) reported that a 36-month study of its VNS Therapy for Drug-Resistant Epilepsy showed a 73% reduction in seizure-related hospitalizations, improved quality of life, and sustained benefits. The CORE-VNS study, published in Neuromodulation, involved 531 participants across 16 countries, with 426 completing follow-up. The company highlights the therapy's long-term effectiveness and safety.

stocktitan.net2 min
AUG 7
$LIVNMedAI 8/10

LivaNova PLC Q2 2026 Earnings Call Summary

LivaNova PLC reported record Q2 2026 revenue and EPS, citing double-digit growth in Cardiopulmonary and Epilepsy. It raised full-year 2026 guidance to 8% to 9% revenue growth and adjusted EPS to $4.30 to $4.40, while lowering adjusted free cash flow to $140m to $160m. Key drivers included Essenz HLM upgrades, oxygenator share gains, and higher Medicare reimbursement.

yahoo.com7 min
AUG 5
$LIVNHighAI 9/10

LivaNova Q2 Earnings Call Highlights

LivaNova (NASDAQ:LIVN) reported Q2 call updates on oxygenator output, citing manufacturing improvements and better third-party component availability, plus a long-term supply agreement with Thermo Fisher Scientific to ease a component constraint. The company raised 2026 cardiopulmonary revenue growth to 9.5% to 10.5% and epilepsy growth to 7% to 8%. Adjusted gross margin was 71% and adjusted diluted EPS guidance was raised to $4.30 to $4.40.

yahoo.com6 min